Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EM-100 vs Zaditor in Allergic Conjunctivitis
NCT03489941Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketotifen in allergic conjunctivitis (AC) (3 arms), sponsored by Bausch + Lomb. Primary endpoint: Ocular Itching at 7 minutes. Started Apr 2018; status: completed.
02
Drugs
ketotifen
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT03489941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489941.